ABVC BioPharma, Inc. ABVC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

42/100

2/7 Pass

SharesGrow Intrinsic Value

$15.87

+1111.5%

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

ABVC BioPharma, Inc. (ABVC) generated $-2.99M in operating cash flow for fiscal year 2025. After capital expenditures of $5.79K, free cash flow was $-2.99M.

Free cash flow margin was -375.9% of revenue.

Criteria supported by this page:

HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat

Overall SharesGrow Score: 42/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

42/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✗

HEALTH

33/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

50/100

Proven by this page

✓

GROWTH

83/100

→ Income

✗

INCOME

10/100

→ Income

ABVC BioPharma, Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$291.62K	$-2.99M	$-1.81M	$-4.24M	$-7.4M
Capital Expenditure	$0.00	$-5.79K	$0.00	$-21.2K	$-119.69K
Free Cash Flow	$291.62K	$-2.99M	$-1.81M	$-4.26M	$-7.52M